Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FabrinetFN · Entity 1696 | Director | May 22, 2026 | May 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fabrinet
Report date May 22, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 16,233 |
Reported balance
After 2026-05-22 transaction · row 1
1 source rowRow 1 · 2026-05-22 · Sale · Disposed 2,500 · Balance 16,233 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
FEI CO
Report date September 19, 2016 · Filed September 21, 2016
Section 16 reporting ended · disclosed 2016-09-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2016-09-19 transaction · row 1
1 source rowRow 1 · 2016-09-19 · Other · Disposed 7,430 · Balance 0 F1: Disposed of at the effective time of the merger of Polpis Merger Sub Co. ("Merger Sub"), a wholly owned subsidiary of Thermo Fisher Scientific Inc. ("Thermo Fisher"), with and into the Issuer (the "Merger"), pursuant to that certain Agreement and Plan of Merger dated May 26, 2016, between the Issuer, Thermo Fisher and Merger Sub (the "Merger Agreement"), in exchange for a cash payment of $107.50 per share. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $69.44 · Expires 2020-05-09 | Direct | 0 |
Reported balance
After 2016-09-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-09-19 · Disposition to issuer · Disposed 2,683 · Balance 0 F2: The option became fully vested on April 30, 2014. At or immediately prior to the effective time of the Merger, the unexercised portion of the option was cancelled in exchange for a cash payment equal to (x) the difference between $107.50 and the per share exercise price of the option, multiplied by (y) the number of shares subject to such portion of the option. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $81.89 · Expires 2021-05-08 | Direct | 0 |
Reported balance
After 2016-09-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-09-19 · Disposition to issuer · Disposed 2,666 · Balance 0 F3: The option became fully vested on April 30, 2015. At or immediately prior to the effective time of the Merger, the unexercised portion of the option was cancelled in exchange for a cash payment equal to (x) the difference between $107.50 and the per share exercise price of the option, multiplied by (y) the number of shares subject to such portion of the option. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $76.31 · Expires 2022-05-07 | Direct | 0 |
Reported balance
After 2016-09-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2016-09-19 · Disposition to issuer · Disposed 3,911 · Balance 0 F4: The option became fully vested on April 30, 2016. At or immediately prior to the effective time of the Merger, the unexercised portion of the option was cancelled in exchange for a cash payment equal to (x) the difference between $107.50 and the per share exercise price of the option, multiplied by (y) the number of shares subject to such portion of the option. |
| RSUsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2016-09-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2016-09-19 · Disposition to issuer · Disposed 1,685 · Balance 0 F5: Each of the restricted share units ("RSUs") represents the right to receive, following vesting, one share of the Issuer's common stock. These RSUs do not expire, unless forfeited under the terms of the RSUs. F6: The RSUs became fully vested on April 30, 2016. At or immediately prior to the effective time of the Merger, each RSU was assumed by Thermo Fisher and converted into an award representing a right to receive a cash amount equal to $107.50. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of at the effective time of the merger of Polpis Merger Sub Co. ("Merger Sub"), a wholly owned subsidiary of Thermo Fisher Scientific Inc. ("Thermo Fisher"), with and into the Issuer (the "Merger"), pursuant to that certain Agreement and Plan of Merger dated May 26, 2016, between the Issuer, Thermo Fisher and Merger Sub (the "Merger Agreement"), in exchange for a cash payment of $107.50 per share.
F2: The option became fully vested on April 30, 2014. At or immediately prior to the effective time of the Merger, the unexercised portion of the option was cancelled in exchange for a cash payment equal to (x) the difference between $107.50 and the per share exercise price of the option, multiplied by (y) the number of shares subject to such portion of the option.
F3: The option became fully vested on April 30, 2015. At or immediately prior to the effective time of the Merger, the unexercised portion of the option was cancelled in exchange for a cash payment equal to (x) the difference between $107.50 and the per share exercise price of the option, multiplied by (y) the number of shares subject to such portion of the option.
F4: The option became fully vested on April 30, 2016. At or immediately prior to the effective time of the Merger, the unexercised portion of the option was cancelled in exchange for a cash payment equal to (x) the difference between $107.50 and the per share exercise price of the option, multiplied by (y) the number of shares subject to such portion of the option.
F5: Each of the restricted share units ("RSUs") represents the right to receive, following vesting, one share of the Issuer's common stock. These RSUs do not expire, unless forfeited under the terms of the RSUs.
F6: The RSUs became fully vested on April 30, 2016. At or immediately prior to the effective time of the Merger, each RSU was assumed by Thermo Fisher and converted into an award representing a right to receive a cash amount equal to $107.50.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 22, 2026 Filed May 22, 2026 21:00 UTC | Fabrinet FN · Entity 1696 | SaleOrdinary Shares | 2,500 | $711.91 | $1,779,775.00 |
DisclosureSEC source: 0001311326-26-000002 · form4-05222026_050501.xml · nonDerivative · entry 1 Bahrami Homa · CIK 0001311326 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,233 Read SEC document |
| December 11, 2025 Filed Dec 13, 2025 01:26 UTC | Fabrinet FN · Entity 1696 | GrantOrdinary Shares | 417 | $0.00 | $0.00 |
DisclosureSEC source: 0001311326-25-000006 · form4-12132025_011243.xml · nonDerivative · entry 1 Bahrami Homa · CIK 0001311326 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,733 F1 · shares: These are restricted share units awarded to the Reporting Person as partial compensation for serving on the Issuer's Board of Directors. Each restricted share unit represents a contingent right to receive one Ordinary Share of Issuer stock and will vest on January 1, 2027, provided the Reporting Person continues to serve through such date. Read SEC document |
| December 01, 2025 Filed Dec 1, 2025 22:41 UTC | Fabrinet FN · Entity 1696 | SaleOrdinary Shares | 3,500 | $453.75 | $1,588,114.50 |
DisclosureSEC source: 0001311326-25-000004 · form4-12012025_101203.xml · nonDerivative · entry 1 Bahrami Homa · CIK 0001311326 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,316 F1 · price: This sale price represents the weighted average sale price of the shares sold ranging from $453.71 to $454.15 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| December 12, 2024 Filed Dec 14, 2024 01:38 UTC | Fabrinet FN · Entity 1696 | GrantOrdinary Shares | 895 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029397 · form4-12142024_011224.xml · nonDerivative · entry 1 Bahrami Homa · CIK 0001311326 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,816 F1 · shares: These are restricted share units awarded to the Reporting Person as partial compensation for serving on the Issuer's Board of Directors. Each restricted share unit represents a contingent right to receive one Ordinary Share of Issuer stock and will vest on January 1, 2026, provided the Reporting Person continues to serve through such date. Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 21:00 UTC | Fabrinet FN · Entity 1696 | SaleOrdinary Shares | 4,500 | $202.46 | $911,088.00 |
DisclosureSEC source: 0001415889-24-004333 · form4-02202024_040201.xml · nonDerivative · entry 1 Bahrami Homa · CIK 0001311326 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,921 F1 · price: This sale price represents the weighted average sale price of the shares sold ranging from $202.27 to $202.62 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 21:27 UTC | Fabrinet FN · Entity 1696 | GrantOrdinary Shares | 1,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-058636 · doc4.xml · nonDerivative · entry 1 Bahrami Homa · CIK 0001311326 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,421 F1 · shares: These are restricted share units awarded to the Reporting Person as partial compensation for serving on the Issuer's Board of Directors. Each restricted share unit represents a contingent right to receive one Ordinary Share of Issuer stock and will vest on January 1, 2025, provided the Reporting Person continues to serve through such date. Read SEC document |
| May 25, 2023 Filed May 26, 2023 20:27 UTC | Fabrinet FN · Entity 1696 | SaleOrdinary Shares | 2,398 | $100.48 | $240,953.44 |
DisclosureSEC source: 0001209191-23-032549 · doc4.xml · nonDerivative · entry 4 Bahrami Homa · CIK 0001311326 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,139 F4 · price: This sale price represents the weighted average sale price of the shares sold ranging from $100.35 to $100.68 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| May 25, 2023 Filed May 26, 2023 20:27 UTC | Fabrinet FN · Entity 1696 | SaleOrdinary Shares | 5,230 | $100.00 | $523,005.23 |
DisclosureSEC source: 0001209191-23-032549 · doc4.xml · nonDerivative · entry 3 Bahrami Homa · CIK 0001311326 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,537 F3 · price: This sale price represents the weighted average sale price of the shares sold ranging from $99.35 to $100.344 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| May 25, 2023 Filed May 26, 2023 20:27 UTC | Fabrinet FN · Entity 1696 | SaleOrdinary Shares | 972 | $98.78 | $96,009.30 |
DisclosureSEC source: 0001209191-23-032549 · doc4.xml · nonDerivative · entry 2 Bahrami Homa · CIK 0001311326 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,767 F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $98.34 to $99.318 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| May 24, 2023 Filed May 26, 2023 20:27 UTC | Fabrinet FN · Entity 1696 | SaleOrdinary Shares | 1,400 | $98.05 | $137,267.20 |
DisclosureSEC source: 0001209191-23-032549 · doc4.xml · nonDerivative · entry 1 Bahrami Homa · CIK 0001311326 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,739 F1 · price: This sale price represents the weighted average sale price of the shares sold ranging from $98.00 to $98.13 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| December 08, 2022 Filed Dec 12, 2022 21:51 UTC | Fabrinet FN · Entity 1696 | GrantOrdinary Shares | 1,679 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-060720 · doc4.xml · nonDerivative · entry 1 Bahrami Homa · CIK 0001311326 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,139 F1 · shares: These are restricted share units awarded to the Reporting Person as partial compensation for serving on the Issuer's Board of Directors. Each restricted share unit represents a contingent right to receive one Ordinary Share of Issuer stock and will vest on January 1, 2024, provided the Reporting Person continues to serve through such date. Read SEC document |
| December 09, 2021 Filed Dec 11, 2021 01:36 UTC | Fabrinet FN · Entity 1696 | GrantOrdinary Shares | 1,746 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-069144 · doc4.xml · nonDerivative · entry 1 Bahrami Homa · CIK 0001311326 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,460 F1 · shares: These are restricted share units awarded to the Reporting Person as partial compensation for serving on the Issuer's Board of Directors. Each restricted share unit represents a contingent right to receive one Ordinary Share of Issuer stock and will vest on January 1, 2023, provided the Reporting Person continues to serve through such date. Read SEC document |
| December 10, 2020 Filed Dec 21, 2020 21:16 UTC | Fabrinet FN · Entity 1696 | GrantOrdinary Shares | 2,890 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-064625 · doc4.xml · nonDerivative · entry 1 Bahrami Homa · CIK 0001311326 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,714 F1 · shares: These are restricted share units awarded to the Reporting Person as partial compensation for serving on the Issuer's Board of Directors. Each restricted share unit represents a contingent right to receive one Ordinary Share of Issuer stock and will vest on January 1, 2022, provided the Reporting Person continues to serve through such date. Read SEC document |
| December 12, 2019 Filed Dec 14, 2019 00:27 UTC | Fabrinet FN · Entity 1696 | GrantOrdinary Shares | 3,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-060511 · doc4.xml · nonDerivative · entry 1 Bahrami Homa · CIK 0001311326 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,824 F1 · shares: These are restricted stock units awarded to the Reporting Person as partial compensation for serving on the Issuer's Board of Directors. Each restricted stock unit represents a contingent right to receive one Ordinary Share of Issuer stock and will vest on January 1, 2021, provided the Reporting Person continues to serve through such date. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 21:19 UTC | Fabrinet FN · Entity 1696 | SaleOrdinary Shares | 6,547 | $60.37 | $395,222.75 |
DisclosureSEC source: 0001209191-19-058344 · doc4.xml · nonDerivative · entry 1 Bahrami Homa · CIK 0001311326 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,650 F1 · price: This sale price represents the weighted average sale price of the shares sold ranging from $60.261 to $60.58 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| December 13, 2018 Filed Dec 14, 2018 23:56 UTC | Fabrinet FN · Entity 1696 | GrantOrdinary Shares | 4,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-062813 · doc4.xml · nonDerivative · entry 1 Bahrami Homa · CIK 0001311326 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,197 F1 · shares: These are restricted stock units awarded to the Reporting Person as partial compensation for serving on the Issuer's Board of Directors. Each restricted stock unit represents a contingent right to receive one Ordinary Share of Issuer stock and will vest on January 1, 2020, provided the Reporting Person continues to serve through such date. Read SEC document |
| December 14, 2017 Filed Dec 26, 2017 21:36 UTC | Fabrinet FN · Entity 1696 | GrantOrdinary Shares | 5,581 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-067218 · doc4.xml · nonDerivative · entry 1 Bahrami Homa · CIK 0001311326 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,090 F1 · shares: These are restricted stock units awarded to the Reporting Person as partial compensation for serving on the Issuer's Board of Directors. Each restricted stock unit represents a contingent right to receive one Ordinary Share of Issuer stock and will vest on January 1, 2019, provided the Reporting Person continues to serve through such date. Read SEC document |
| December 15, 2016 Filed Dec 28, 2016 21:29 UTC | Fabrinet FN · Entity 1696 | GrantOrdinary Shares | 2,893 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-156893 · doc4.xml · nonDerivative · entry 1 Bahrami Homa · CIK 0001311326 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,509 F1 · shares: These are restricted stock units awarded to the Reporting Person as partial compensation for serving on the Issuer's Board of Directors. Each restricted stock unit represents a contingent right to receive one Ordinary Share of Issuer stock and will vest on January 1, 2018, provided the Reporting Person continues to serve through such date. Read SEC document |
| September 19, 2016 Filed Sep 21, 2016 13:38 UTC | FEI CO FEIC · Entity 182178 | Disposition to issuerRSUs · Derivative | 1,685 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-16-029566 · doc4.xml · derivative · entry 5 Bahrami Homa · CIK 0001311326 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,685 shares Expires not disclosed F5 · derivative.exercise_price: Each of the restricted share units ("RSUs") represents the right to receive, following vesting, one share of the Issuer's common stock. These RSUs do not expire, unless forfeited under the terms of the RSUs. F6 · price: The RSUs became fully vested on April 30, 2016. At or immediately prior to the effective time of the Merger, each RSU was assumed by Thermo Fisher and converted into an award representing a right to receive a cash amount equal to $107.50. F5 · derivative.expiration_date: Each of the restricted share units ("RSUs") represents the right to receive, following vesting, one share of the Issuer's common stock. These RSUs do not expire, unless forfeited under the terms of the RSUs. Read SEC document |
| September 19, 2016 Filed Sep 21, 2016 13:38 UTC | FEI CO FEIC · Entity 182178 | Disposition to issuerStock Options · Derivative | 3,911 | Not disclosed Strike: $76.31 | Not disclosed |
DisclosureSEC source: 0000899243-16-029566 · doc4.xml · derivative · entry 4 Bahrami Homa · CIK 0001311326 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,911 shares Expires 2022-05-07 F4 · price: The option became fully vested on April 30, 2016. At or immediately prior to the effective time of the Merger, the unexercised portion of the option was cancelled in exchange for a cash payment equal to (x) the difference between $107.50 and the per share exercise price of the option, multiplied by (y) the number of shares subject to such portion of the option. Read SEC document |
| September 19, 2016 Filed Sep 21, 2016 13:38 UTC | FEI CO FEIC · Entity 182178 | Disposition to issuerStock Options · Derivative | 2,666 | Not disclosed Strike: $81.89 | Not disclosed |
DisclosureSEC source: 0000899243-16-029566 · doc4.xml · derivative · entry 3 Bahrami Homa · CIK 0001311326 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,666 shares Expires 2021-05-08 F3 · price: The option became fully vested on April 30, 2015. At or immediately prior to the effective time of the Merger, the unexercised portion of the option was cancelled in exchange for a cash payment equal to (x) the difference between $107.50 and the per share exercise price of the option, multiplied by (y) the number of shares subject to such portion of the option. Read SEC document |
| September 19, 2016 Filed Sep 21, 2016 13:38 UTC | FEI CO FEIC · Entity 182178 | Disposition to issuerStock Options · Derivative | 2,683 | Not disclosed Strike: $69.44 | Not disclosed |
DisclosureSEC source: 0000899243-16-029566 · doc4.xml · derivative · entry 2 Bahrami Homa · CIK 0001311326 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,683 shares Expires 2020-05-09 F2 · price: The option became fully vested on April 30, 2014. At or immediately prior to the effective time of the Merger, the unexercised portion of the option was cancelled in exchange for a cash payment equal to (x) the difference between $107.50 and the per share exercise price of the option, multiplied by (y) the number of shares subject to such portion of the option. Read SEC document |
| September 19, 2016 Filed Sep 21, 2016 13:38 UTC | FEI CO FEIC · Entity 182178 | OtherCommon Stock | 7,430 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-16-029566 · doc4.xml · nonDerivative · entry 1 Bahrami Homa · CIK 0001311326 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of at the effective time of the merger of Polpis Merger Sub Co. ("Merger Sub"), a wholly owned subsidiary of Thermo Fisher Scientific Inc. ("Thermo Fisher"), with and into the Issuer (the "Merger"), pursuant to that certain Agreement and Plan of Merger dated May 26, 2016, between the Issuer, Thermo Fisher and Merger Sub (the "Merger Agreement"), in exchange for a cash payment of $107.50 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.